BioCentury
ARTICLE | Clinical News

Lorus starts pancreatic cancer Phase III

November 20, 2001 8:00 AM UTC

Lorus (TSE:LOR; LORFF) started a North American 350-patient Phase III study of its Virulizin to treat advanced pancreatic cancer. Patients will receive gemcitabine or a combination of gemcitabine and ...